ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L08

Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders

Christopher Podgorski1 and Deborah Parks2, 1BJC/Washington University Consortium, St. Louis, MO, 2Washington University/B-JH/SLCH Consortium, St. Louis, MO

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: COVID-19, Late-Breaking 2022, prevention, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: (L07–L17) Late-Breaking Abstract Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The dose was increased to 300/300 mg on 2/25/22. True efficacy of protection from breakthrough COVID-19 infection in immunosuppressed patients with rheumatic disorders, especially against emerging Omicron subvariants, is not well-established. A European study reported a breakthrough rate of 4.4% in a heterogeneous group of immunocompromised patients receiving tixagevimab/cilgavimab 150/150 with median followup of 63 days. A recent US cohort of 43 rheumatic patients receiving rituximab showed a 4.32% breakthrough rate after an average of 100 days. Real world data reflecting the recommended 6-month dosing interval in rheumatic patients remains lacking.

Methods: Longitudinal study of rheumatic patients initially dosed with tixagevimab/cilgavimab contacted at 6 months for redosing and questioned regarding interval COVID-19 infection with confirmation by manual chart review as well as retrospective chart review of patients who had not achieved a 6-month interval from last dose for rate of breakthrough COVID-19 infection.

Results: 157 patients received Tixagevimab/Cilgavimab from 1/16/22– 8/31/22 with average follow up of 154 days. Disease distribution is reported in Table 1 and treatment regimens in Table 2. Due to limited resources, initial allocation was given to patients on B cell depleting therapy. After 2/22, all patients meeting FDA guidelines were offered monoclonal prophylaxis.

No serious adverse events occurred. There were 24 cases (15.3%) of breakthrough acute COVID-19 infection following Tixagevimab/Cilgavimab administration. There was an average of 99.5 days (ranging from 5-195 days) between the last dose and the date of breakthrough infection. These patients were predominantly female (87.5%), Caucasian (87.5%), averaging 60.5 years old (ranging 20-81 years). All patients were fully vaccinated against COVID-19, and 4 had a prior COVID-19 infection. Three patients received doses of 150/150 mg without makeup doses and 21 received 300/300 mg doses. Sixteen (66.6%) received post-exposure oral antiviral therapy. Most patients experienced mild to moderate symptoms but two patients, who both received the 300/300 mg dose, required hospitalization. 37.6 % receiving tixagevimab/cilgavimab were on rituximab and of these, 29% experienced symptomatic breakthrough COVID-19 infection. There were no deaths.

Conclusion: Following treatment with Tixagevimab/Cilgavimab, 15.3% of fully vaccinated rheumatic patients experienced symptomatic breakthrough COVID-19 infection during a period when Omicron subvariants were dominant, peaking in our region with a weekly incidence of 522 cases/100K population. Treatment with rituximab was a common risk factor in 70.8% of these breakthrough cases with ~ 1/3 of rituximab treated patients receiving monoclonal prophylaxis experiencing symptomatic mild to moderate infections. These breakthrough rates are significantly higher than previously reported. Ongoing evaluation of best practices for repeat dosing and intervals of Tixagevimab/Cilgavimab is needed.

Supporting image 1

Table 1. COVID_19 Breakthrough in Patients receiving Prophylactic Tixagevimab/CilgavimabACR image 1

Supporting image 2

Table 2. Therapeutic regimens in Patients experiencing Breakthrough COVID_19 Infections


Disclosures: C. Podgorski, None; D. Parks, None.

To cite this abstract in AMA style:

Podgorski C, Parks D. Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/breakthrough-acute-covid-19-infection-during-the-us-omicron-surge-following-administration-of-tixagevimab-cilgavimab-in-immunocompromised-patients-with-rheumatologic-disorders/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/breakthrough-acute-covid-19-infection-during-the-us-omicron-surge-following-administration-of-tixagevimab-cilgavimab-in-immunocompromised-patients-with-rheumatologic-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology